http___hr.adaptogens.com_c-13227.aspx_1.xml
1.1 1.2 1.3 1.4 2.1 3.1 4.1 4.2 4.3 5.1 6.1 6.2 7.1 8.1 8.2 8.3 8.4 8.5 8.6 9.1 9.2 9.3
A man like a long-lived organism has excellent antitumor defense . Year after year, our immune system eliminates, without our knowledge, the tumors arising in our body. Only when bad luck and the tumor "does not catch", we will get cancer. Therefore, cancer can be considered as an immune failure. The thing is even clearer when we realize that children with congenital immune deficiency (such as the famous "bubble baby") dying for cancer at an early age even when doctors, with the help of a bubble and antibiotics , are able to protect them from a fatal infection to which Would normally die. It is therefore understandable that immunostimulatory adaptogens have a chance to influence the course of the cancer. And thus assign the work to the immune system that normally destroys the malignant tumors that are constantly arising in our body both on the running belt. If any of the cancer-causing tumors escape, we may even die of cancer. This is the principle of tumor risk after irradiation. How immunotherapy works However, these methods fail with extensive metastases. In these cases, so-called biological treatment (bio-therapy), more correctly immunological treatment. Chemotherapy can sometimes partially protect healthy cells by targeted infusion of affected organs (performed since the 1950s) or by bone marrow autotransplantation. Immunotherapy for cancer is nothing new. There has long been an effort to create anticancer vaccines. Here, however, is the problem that the patient's own immune system is usually heavily damaged by cytostatic therapy. In today's immunotherapy, therefore, anti-cancer cells are artificially engineered and administered to the patient intravenously. This is not a miraculous method. The physician actually imitates the immune system of the patient, and in doing so faces a challenge in which the natural immunity has failed once. I consider the effort to combine antibodies with a-radioisotopes, which then locally irradiate small tumorous deposits (targeted alpha therapy). Targeted alpha therapy was devoted, for example, to No. 3 of Current Radiopharmaceuticals from September 2008 , from specific publications such as Tolmachev2007rth (lutetium 177 + HER2 anti- breast cancer antibodies ) and Liepe2009a2a (Alpharadin, Prostate Cancer Radiation 223). Research activity is progressing intensively in this field, see Gudkov2016trt for an overview.
1.1 1.2 1.3 1.4 2.1 2.2 3.1 4.1 4.2 4.3 5.1 6.1 6.2 6.3 7.1 8.1 8.2 8.3 8.4 8.5 8.6 9.1 9.2 9.3 9.4 9.5
Jedna takva dugovječna organizam ima odličan anti-tumorskih obranu . Iz godine u godinu, naš imunološki sustav bez naših tumora znanja nastaju u našem tijelu. Kada je ima peh i tumor „ne uhvati” bolesna od raka. Dakle, rak se može smatrati bitno imunološki neuspjeh. Stvar je još jasnije kada smo shvatili da djeca s prirođenim manjka imuniteta (npr. Poznati „balon beba”) umiru od raka u ranoj dobi, čak i ako liječnici za pomoć mjehurića i antibiotici će štititi protiv smrtonosnih infekcija , koje inače umrijeti. Stoga je razumljivo da su imunostimulirajuće adaptogens imaju priliku utjecati na tijek raka. přidělají i rad imunološkog sustava, koje obično maligni tumori koji proizlaze iz našeg stalno uništava tijelo kao alva. Ako bilo koji od nastalih tumora bijeg razaranja, možemo čak umrijeti od raka. To je princip rizik od raka nakon izlaganja. Kako imunoléčba No, ove metode ne uspiju za velike metastaza. U tim slučajevima, tu se sada zove. Biološka terapija (bioléčba) ispravno imunološka obrada. Kad kemoterapija može ponekad biti djelomično štiti zdrave stanice ciljano perfuziju zahvaćenih organa (učinio još od 50-tih godina 20. stoljeća) ili Autotransplantacija koštane srži. Rak Imunoléčba nije ništa novo. Davno je bilo nastojanje za stvaranje cjepiva protiv raka. Ali ovdje je problem da se pacijentovo vlastiti imunološki sustav obično se teško oštetile terapije sa citostaticima. Trenutno, dakle imunoléčbě antitijela protiv stanica karcinoma, a proizvode se umjetno primjenjuje intravenski na pacijentu. No, ni to nije čudesan način. Liječnik zapravo samo oponaša pacijenta imunološki sustav i time stoji pred zadatkom u kojem jedan ima prirodni imunitet nije uspio. Za ispravan pokušaji kombinirati protutijela s a-radioizotopi, koji zatim lokalno isijavaju mala žarišta tumora (ciljana terapija alfa). Ciljane a terapija je posvećena primjeru br. 3. Tekući radiofarmaka rujna 2008. , od posebne publikacija npr Tolmachev2007rth (lutecij-177 HER2 protutijela protiv raka dojke ) i Liepe2009a2a (Alpharadin, radij 223 karcinom prostate). Istraživanje aktivnosti u ovom području napreduje intenzivno, za pregled vidi Gudkov2016trt .